Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Notice of Special Interest (NOSI): Chemoproteomic Approaches for Discovery of Targets and Therapeutics to Treat Substance Use Disorders

National Institutes of Health

The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse ( NIDA ) about a special interest in supporting basic research on the application of chemoproteomic approaches for the discovery of targets and for development of drugs to treat addiction and substance use disorders.

Chemoproteomics combines diverse approaches in synthetic chemistry, cell biology and mass spectrometry to covalently modify, identify, and characterize protein targets of interest for drug discovery. Chemical proteomic platforms such as the activity-based protein profiling (ABPP) have proven effective for identifying drug targets in various biological settings. Use of reactivity-based chemical probes and advanced quantitative mass spectrometry-based proteomic techniques have enabled identification of hotspots for ligand binding on proteins including those that are generally considered undruggable. Chemoproteomic methods also enable identification of allosteric binding sites that could be targeted with small molecules to modulate the function of the target proteins. These chemoproteomic approaches, together with emerging technologies such as targeted protein degradation, covalent fragment-based ligand discovery, and biorthogonal chemistry, are transforming the landscape of drug discovery. Development of novel chemoproteomic methods and their application, therefore, holds considerable potential for identifying and illuminating targets of relevance to substance use and for providing leads for the development of drugs for treating substance use disorders.

The goal of this announcement is to encourage preclinical research aimed at developing and applying chemoproteomic approaches to identify targets of relevance to substance use disorders and to develop novel pharmacological tools, methods, and therapeutic interventions for the treatment of substance use disorders and addiction.

This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026.

NOT-DA-24-005

Specialties

Others

Substance Use Disorders

Rehabilitation Medicine

Eligibility Requirements

This notice applies to due dates on or after February 5, 2023 and subsequent receipt dates through January 8, 2026.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity